Response of fibroblast growth factor 19 and bile acid synthesis after a body weight-adjusted oral fat tolerance test in overweight and obese NAFLD patients: a non-randomized controlled pilot trial

Non-alcoholic fatty liver disease (NAFLD) is common both in obese and overweight patients. Fibroblast growth factor 19 (FGF19), an intestinal hormone, could play a role in the complex pathogenesis of NAFLD. Th...

https://bmcgastroenterol.biomedcentral.com/articles/10.1186/s12876-018-0805-z

Source: BMC Gastroenterology - June 4, 2018 Category: Gastroenterology Authors: Dana Friedrich, Hanns-Ulrich Marschall and Frank Lammert Tags: Research article Source Type: research